00:00Eli Lilly unveiled a new multi-dose version of its blockbuster obesity drug ZetBound,
00:06allowing patients to receive a full month of doses in a single injection pen.
00:11Available to cash-paying customers through the company's direct-to-consumer platform,
00:16Lilly Direct, it starts at $299 per month for the lowest dose and offers a more convenient
00:23alternative to weekly single-use injectors. The move comes as Lilly works to maintain
00:28ZetBound's rapid growth, which has helped the company overtake rival Novo Nordisk in the weight
00:34loss drug market, and generated $4.2 billion in U.S. sales in the fourth quarter, a 122% year
00:42-over-year
00:43jump. The FDA has approved a label expansion for the multi-dose device, which is already used for
00:49other Lilly medications, including its diabetes drug, Manjaro.
Comments